The first country in Europe Abandoning AstraZeneca’s COVID-19 Vaccine In April, Denmark announced on Monday that it would abandon Johnson & Johnson due to potentially dangerous side effects, despite the green lights from the European regulator and the World Health Organization to use it.
“The Danish National Health Authority concluded that the benefits of using the Johnson & Johnson Covid-19 vaccine do not outweigh the risks of causing a potential side effect, VITT (a very rare type of thrombosis associated with injection of serum) in people and said in a statement,“ who receive the vaccine. ”
Also read: Denmark drops AstraZeneca vaccine
Therefore, Denmark “will continue the Danish comprehensive vaccination program for Covid-19 without the Johnson & Johnson vaccine,” it announced.
Denmark, which appears with this decision among the first in the world to abandon it, has never authorized the vaccine, which was marketed in Europe by Janssen, a subsidiary of J&J. His job has been evaluated or not since mid-April.
This decision will slow down the current vaccination campaign in the northern country by four weeks, where the epidemic is considered “under control” and where the majority of people at risk and health care workers have been vaccinated.
Anyone over 16 years of age who wants to be vaccinated should be able at the end of August.
According to the latest tally, 11.5% of the 5.8 million Danes were completely vaccinated, and 23.4% received a first injection.
Four vaccines are currently authorized in the European Union: Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson – the latter two under certain age conditions in most European countries.
In the report, Deputy Director-General of the Danish Health Authority, Helen Probst, said: “It must also be taken into account that in the future we will first and foremost vaccinate young and healthy people.”
In April, the US regulatory agency temporarily stopped the use of the Johnson & Johnson vaccine after rare cases of blood clots.
In Europe, the EMA estimated that it benefited from a favorable benefit / risk ratio despite the presence of a “very rare” risk of blood clots.
Denmark has ordered 8.2 million doses of the vaccine, the first of which was received in mid-April.
It has not yet been indicated what will happen to the doses received, but discussions are underway in the Scandinavian Kingdom to allow the injection of this vaccine and AstraZeneca vaccine to whomever they wish.
Health authorities have not ruled out reintroducing the Johnson & Johnson vaccine, or AstraZeneca, into the immunization program in the future.
“New knowledge may emerge, or the situation in Denmark may change, for example in terms of epidemiological pressure (…) or the availability of other vaccines,” the authority said.
According to an AFP count, Johnson & Johnson has been in use in 17 countries so far, including France, the United States, Spain, and Poland.
AstraZeneca vaccine is given in nearly 160 countries, and Pfizer vaccine is given in about 80 countries and Modena in about 40 countries.